METHOD OF IMPROVING LENS ROTATION

• US 20110262519A1
• Filed: 04/20/2011
• Published: 10/27/2011
• Est. Priority Date: 04/23/2010
• Status: Abandoned Application

• Current Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Original Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Inventors: Hansen, Jonathan, Moody, Kurt, Franklin, Ross
• Application Number:
  US13/091,078
• Publication Number:
  US 20110262519A1
• Time in Patent Office: Days
• US Class Current: 424/429
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: B29D 11/00134 Curing of the contact lens material

Abstract

Ophthalmic stabilized lenses have improved rotational properties by treating them with a wetting agent after they are at least initially polymerized.

Claims

1. A method of improving the rotational properties of a stabilized ophthalmic lenses comprising, treating a polymerized stabilized ophthalmic lens with a wetting agent, provided that the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization.

2. The method of claim 1 wherein treating comprises heating the polymerized ophthalmic lens in a packaging solution.

3. The method of claim 2 wherein the polymerized ophthalmic lens is heated to a temperature of at least about greater than 50°

C. to about 150°

C.

4. The method of claim 1 wherein the packaging solution comprises deionized water, or saline solution.

5. The method of claim 1 wherein the packaging solution comprises about 1870 ppm to about 18,700 ppm sodium borate

6. The method of claim 1 wherein the packaging solution comprises about 3700 ppm sodium borate.

7. The method of claim 1 wherein the packaging solution comprises about 2000 ppm to about 5000 ppm sodium borate.

8. The method of claim 1 wherein the wetting agent is selected from the group consisting of poly(meth)acrylamides, poly(itaconic acid), hyaluronic acid, xanthan gum, gum Arabic, starch, polymers of hydroxylalkyl(meth)acrylates, and polyvinylpyrrolidone.

9. The method of claim 1 wherein the wetting agent is selected from the group consisting of polyvinylpyrrolidone, graft co-polymers of polyvinylpyrrolidone, and co-polymers of polyvinylpyrrolidone.

10. The method of claim 1 wherein the wetting agent is polyvinylpyrrolidone.

11. The method of claim 10 wherein the K-value of the polyvinylpyrrolidone is about K-60 to about K-120.

12. The method of claim 10 wherein the K-value of the polyvinylpyrrolidone is about K-85 to about K-95.

13. The method of claim 10 wherein the K-value of polyvinylpyrrolidone is about K-90.

14. The method of claim 1 wherein treating comprises heating the polymerized ophthalmic lens in a packaging solution comprising polyvinylpyrrolidone having a K-value of about K-85 to about K-95 at a temperature of greater than about 80°

C.

15. The method of claim 1 wherein treating comprises heating the polymerized ophthalmic lens in a packaging solution comprising polyvinylpyrrolidone having a K-value of about K-85 to about K-95 at a temperature of greater than about 120°

C.

16. The method of claim 2 wherein the wetting agent is polyvinylpyrrolidone and the concentration of polyvinylpyrrolidone in the packaging solution is about 250 ppm to about 2500 ppm.

17. The method of claim 2 wherein the concentration of wetting agent in the packaging solution is about 100 ppm to about 3000 ppm.

18. The method of claim 1 wherein the polymerized ophthalmic lens is heated at about 124°

C. for about 18 minutes and with polyvinylpyrrolidone having a K-value of about K-90 at a concentration of about 400 to about 440 ppm.

19. The method of claim 1 wherein the polymerized ophthalmic lens is heated at about 121°

C. for about 30 minutes and with polyvinylpyrrolidone having a K-value of about K-90 at a concentration of about 300 to about 400 ppm.

20. The method of claim 2 wherein the treating step is conducted in an individual sealed contact lens package.

21. The method of claim 17 wherein the treating step is conducted in an individual sealed contact lens package.

22. The method of claim 18 wherein the treating step is conducted in an individual sealed contact lens package.

23. The method of claim 1 wherein the ophthalmic lens is selected from the group consisting of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A.

24. The method of claim 2 wherein the ophthalmic lens is selected from the group consisting of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A.

25. The method of claim 14 wherein the ophthalmic lens is selected from the group consisting of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A.

26. The method of claim 2 wherein the ophthalmic lens is selected from the group consisting of genfilcon A, lenefilcon A, lotrafilcon A, lotrafilcon B, balafilcon A, comfilcon, etafilcon A, nelfilcon A, hilafilcon, and polymacon.

27. The method of claim 14 wherein the ophthalmic lens is selected from the group consisting of genfilcon A, lenefilcon A, lotrafilcon A, lotrafilcon B, balafilcon A, comfilcon, etafilcon A, nelfilcon A, hilafilcon, and polymacon.

28. The method of claim 2 wherein the ophthalmic lens is selected from the group consisting of etafilcon A, nelfilcon A, hilafilcon, and polymacon.

29. The method of claim 14 wherein the ophthalmic lens is selected from the group consisting of etafilcon A, nelfilcon A, hilafilcon, and polymacon.

30. The method of claim 2 wherein the ophthalmic lens is selected from the group consisting of etafilcon A.

31. The method of claim 14 wherein the ophthalmic lens is selected from the group consisting of etafilcon A.

32. The method of claim 18 wherein the ophthalmic lens is an etafilcon A contact lens.

33. The method of claim 1 wherein the polymerized ophthalmic lens is an un-hydrated polymerized ophthalmic lens.

34. The method of claim 33 wherein treating comprises contacting the un-hydrated polymerized ophthalmic lens with a packaging solution comprises about 1870 ppm to about 18,700 ppm sodium borate.

35. The method of claim 33 wherein the treating further comprises heating the un-hydrated polymerized ophthalmic lens and packaging solution to a temperature of at least about 50°

C. to about 100°

C.

36. The method of claim 33 wherein the treating further comprises maintaining the un-hydrated polymerized ophthalmic lens and packaging solution at a temperature of at least about 10°

C. to about room temperature.

37. The method of claim 34 wherein the packaging solution further comprises deionized water, or saline solution.

38. The method of claim 33 wherein the wetting agent is selected from the group consisting of poly(meth)acrylamides, poly(itaconic acid), hyaluronic acid, xanthan gum, gum Arabic, starch, polymers of hydroxylalkyl(meth)acrylates, and polyvinylpyrrolidone.

39. The method of claim 33 wherein the wetting agent is selected from the group consisting of polyvinylpyrrolidone, graft co-polymers of polyvinylpyrrolidone, and co-polymers of polyvinylpyrrolidone.

40. The method of claim 33 wherein the wetting agent is polyvinylpyrrolidone.

41. The method of claim 33 wherein the K-value of the polyvinylpyrrolidone is about K-60 to about K-120.

42. The method of claim 33 wherein the K-value of the polyvinylpyrrolidone is about K-60 to about K-90.

43. The method of claim 40 wherein the polyvinylpyrrolidone is present at a concentration of about 30,000 ppm to about 150,000 ppm.

44. The method of claim 34, further comprising a second step of heating the un-hydrated polymerized ophthalmic lens of claim 34 with a second portion of packaging solution comprising a second wetting agent.

45. The method of claim 44 wherein the wetting agent is polyvinylpyrrolidone having a K-value of about K-60 and the second wetting agent is polyvinylpyrrolidone having a K-value of about K-90.

46. The method of claim 44 wherein the wetting agent is polyvinylpyrrolidone having a K-value of about K-90 and the second wetting agent is polyvinylpyrrolidone having a K-value of about K-90.

47. The method of claim 45 wherein the concentration of K₆₀ is between about 30,000 ppm and 150,000 about ppm and the concentration of K₉₀ is between about 100 ppm and about 500 ppm.

48. An ocular device comprising a polymerized stabilized ophthalmic lens wherein said polymerized stabilized ophthalmic lens is treated with a wetting agent, provided that the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerization.

49. The device of claim 48 wherein the wetting agent is selected from the group consisting of poly(meth)acrylamides, poly(itaconic acid), hyaluronic acid, xanthan gum, gum Arabic, starch, polymers of hydroxylalkyl(meth)acrylates, and polyvinylpyrrolidone.

50. The device of claim 48 wherein the wetting agent is polyvinylpyrrolidone, graft co-polymers of polyvinylpyrrolidone, and co-polymers of polyvinylpyrrolidone.

51. The device of claim 48 wherein the wetting agent is polyvinylpyrrolidone.

52. The device of claim 48 comprising about 0.01 mg to about 1.0 mg polyvinylpyrrolidone.

53. The device of claim 48 comprising about 0.10 mg to about 0.44 mg of polyvinylpyrrolidone.

54. The device of claim 48 wherein said device does not distort the user'"'"'s vision.

55. The device of claim 48 comprising about 0.01 mg to about 1.0 mg of a wetting agent selected from the group consisting of poly(meth)acrylamides, poly(itaconic acid), hyaluronic acid, xanthan gum, gum Arabic, starch, polymers of hydroxylalkyl(meth)acrylates, and polyvinylpyrrolidone.

56. The device of claim 48 comprising about 0.10 mg to about 0.44 mg of poly(meth)acrylamides, poly(itaconic acid), hyaluronic acid, xanthan gum, gum Arabic, starch, polymers of hydroxylalkyl(meth)acrylates, and polyvinylpyrrolidone.

57. The device of claim 48 wherein said device does not distort the user'"'"'s vision.

58. The device of claim 48 wherein said wetting agent remains in the ophthalmic lens after about 6 hours to about 24 hours of wear by a user.

59. An ocular device prepared by treating a polymerized ophthalmic lens with a wetting agent, provided that the ophthalmic lens formulation does not comprise said wetting agent prior to its polymerizaton.

60. The device of claim 59 wherein treating comprises heating the polymerized ophthalmic lens in a packaging solution to a temperature of about greater than 50°

C. to about 150°

C.

61. The device of claim 59, wherein the wetting agent is selected from the group consisting of polyvinylpyrrolidone, graft co-polymers of polyvinylpyrrolidone, and co-polymers of polyvinylpyrrolidone.

62. The device of claim 59 wherein the wetting agent is polyvinylpyrrolidone having a K-value of about K-60 to about K-90.

63. The device claim 59 wherein the ophthalmic lens is selected from the group consisting of acofilcon A, alofilcon A, alphafilcon A, amifilcon A, astifilcon A, atalafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon, crofilcon A, cyclofilcon A, darfilcon A, deltafilcon A, deltafilcon B, dimefilcon A, drooxifilcon A, epsifilcon A, esterifilcon A, etafilcon A, focofilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon D, hilafilcon A, hilafilcon B, hioxifilcon B, hioxifilcon C, hixoifilcon A, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon B, mafilcon A, mesifilcon A, methafilcon B, mipafilcon A, nelfilcon A, netrafilcon A, ocufilcon A, ocufilcon B, ocufilcon C, ocufilcon D, ocufilcon E, ofilcon A, omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, silafilcon A, siloxyfilcon A, tefilcon A, tetrafilcon A, trifilcon A, and xylofilcon A.

64. The device of claim 59 wherein the ophthalmic lens is selected from the group consisting of genfilcon A, lenefilcon A, lotrafilcon A, lotrafilcon B, balifilcon A, comfilcon, etafilcon A, nelfilcon A, hilafilcon, and polymacon.

65. The device of claim 59 wherein the ophthalmic lens is etafilcon A.